Cargando…
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma
AIM: To evaluate the accuracy of melphalan test dose pharmacokinetic (PK) predictions of the subsequent high dose (HDM) area under the concentration-versus-time curve (AUC) and to identify sources of prediction error (PE). METHODS: A prospective multicentre PK study was conducted in 40 myeloma patie...
Autores principales: | Nath, Christa Ellen, Grigg, Andrew, Rosser, Sebastian P. A., Estell, Jane, Newman, Elizabeth, Tiley, Campbell, Ramanathan, Sundra, Ho, Shir Jing, Larsen, Stephen, Gibson, John, Presgrave, Peter, Shaw, Peter John, Trotman, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649448/ https://www.ncbi.nlm.nih.gov/pubmed/36205743 http://dx.doi.org/10.1007/s00228-022-03396-x |
Ejemplares similares
-
Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993) -
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019) -
Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant
por: Cho, Yu Kyoung, et al.
Publicado: (2018) -
Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022) -
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)